The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials
Participants with acute schizophrenia with prespecified impairments demonstrated significant cognitive improvement with xanomeline/trospium compared with placebo. This result directly confirms earlier findings. This benefit is not attributable to changes in symptoms, despite substantial evidence of efficacy for psychosis. Evaluation of xanomeline/trospium's potential for cognitive enhancement in a well-controlled trial of stable patients with cognitive impairment is warranted.
Authors
- Samantha E. Yohn (ORCID: https://orcid.org/0000-0002-3277-4751)
- Colin Sauder (ORCID: https://orcid.org/0000-0002-0151-5191)
- Stephen K. Brannan (ORCID: https://orcid.org/0000-0003-0922-5970)
- Richard S.E. Keefe (ORCID: https://orcid.org/0000-0002-0173-8897)
- Philip D. Harvey (ORCID: https://orcid.org/0000-0002-9501-9366)
- William P. Horan (ORCID: https://orcid.org/0000-0002-0854-6388)
- Ian S. Ramsay (ORCID: https://orcid.org/0000-0002-5823-012X)
- Steven M. Paul (ORCID: https://orcid.org/0000-0002-8388-2023)
- Vicki G. Davis
Institutions
- University of Miami (US)
- Duke University (US)
Publication Details
- Journal
- American Journal of Psychiatry
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1176/appi.ajp.20240076
- Citations
- 37
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 14.27